CapsoVision, Inc. (CV)
NASDAQ:CV
Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$338.75M
Enterprise Value$321.61M
Total Cash (Recent Filing)$17.93M
Total Debt (Recent Filing)$788.00K
Price to Earnings (P/E)―
Beta-1.43
Next Earnings
Aug 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding49,963,585
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue23.71
Enterprise Value/Gross Profit45.89
Enterprise Value/Ebitda-12.07
Forecast
1Y Price Target
$10.50Price Target Upside-20.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$15.80M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & Stable Gross MarginsConsistent double‑digit revenue growth alongside stable mid‑50s gross margins indicates the business model is scaling with healthy unit economics. This durability supports eventual operating leverage and makes future profitability more achievable if operating expenses are controlled.
Progress Toward Operating BreakevenNear‑breakeven operating results signal improving cost structure and operational discipline. Sustainable narrowing of operating losses reduces external funding needs and demonstrates the company can scale toward profitability as revenue continues to grow and fixed costs are absorbed.
Secured Upgraded Image Sensors Via Canon AmendmentLocking in upgraded sensors with Canon secures a critical component for regulatory submissions and clinical performance. This supply and tech alignment strengthens product competitiveness, lowers integration risk and supports a clearer path to regulatory clearance and market adoption.
Bears Say
Sizable Persistent Cash BurnLarge, sustained negative operating and free cash flows materially weaken financial resilience and create ongoing funding requirements. Continued cash burn increases dilution or financing risk, constraining the firm's ability to invest and execute without repeated external capital raises.
Accumulated Losses And Capital Base FragilityA history of deep accumulated losses and volatile equity undermines balance‑sheet durability, raising the probability of dilution or costly financing. Even with low debt, a fragile capital base limits strategic flexibility and heightens investor sensitivity to execution missteps.
Regulatory Setback And Extended Development TimelineStopping the initial FDA path and expanding to a larger pivotal study delays commercial rollout and increases development cost and timeline. Such regulatory pivots amplify execution risk and postpone revenue realization, pressuring cash needs and strategic momentum.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $338.75M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 73 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.13.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,963,585 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -11.575%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
126.84%
Trailing 12-Months
Asset Growth
108.43%
Trailing 12-Months
Company Description
CapsoVision, Inc.
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
CV Earnings Call
Q1 2026
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$10.50
▼(-20.63% Downside)
Technical Analysis
Ownership Overview
2.95% Insiders
2.56% Mutual Funds
0.02% Other Institutional Investors
90.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---